Meningioma – Pipeline Review, H2 2017 – Research and Markets

– Pipeline Review, H2 2017”
report has been added to Research
and Markets’

Meningioma – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Meningioma
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Meningioma (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Meningioma and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase II, Phase I, Phase 0 and Preclinical
stages are 8, 3, 1 and 2 respectively. Similarly, the Universities
portfolio in Preclinical stages comprises 2 molecules, respectively.

Meningioma (Oncology) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Meningioma – Overview
  3. Meningioma – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Meningioma – Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Meningioma – Companies Involved in Therapeutics Development
  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Co
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Pharma Mar SA
  • Progenics Pharmaceuticals Inc

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Brain
Cancer Drugs